An interventional study of CliniMACS (CD+3, CD+19 depletion) and CliniMACS (CD 34+ positive selection) in Malignant Diseases (ie, Leukemia, MDS, Lymphoma) and Non-malignant Diseases (ie, Bone Marrow Failure Syndromes), sponsored by Medical College of Wisconsin. Completed at 1 site in United States. Open to participants aged Up to 22 Years. Per ClinicalTrials.gov, last updated 2021-10-25.
Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Treatment
Among 10 studies in Leukemia by Medical College of Wisconsin — 2 open to participants now, 2 under way, none of them phase 3. Leukemia · Medical College of Wisconsin.
Among the 10 studies in Leukemia by Medical College of Wisconsin, this one is the 5th largest by enrollment, is the only one that started in 2008, is one of 2 with no phase, and was the 4th registered.
2,381 studies on the registry are indexed under Leukemia; 253 are open to participants now.
Browse Leukemia studies →2 of the 10 studies in Leukemia by Medical College of Wisconsin are open now, in 1 country. Recruiting first, the newest first:
Medical College of Wisconsin · Sites in United States
Medical College of Wisconsin · Sites in United States
By country, each count listing its studies:
Of the 208 Leukemia studies recruiting now, 112 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 86 take children under 18; 24 take healthy volunteers.
This study: Up to 22 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2008.
This study's enrollment of 60 is above the median of 40 across 1,769 interventional studies indexed under Leukemia.
Median enrollment 51 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Medical College of Wisconsin is the lead sponsor of 548 studies on the registry; 122 are open to participants now.
Of its 75 completed or terminated interventional studies of FDA-regulated products, 57 (76%) have results posted.
1 of the studies in Leukemia by Medical College of Wisconsin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05794880Medical College of WisconsinMCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing | 2027-05 |
Among the 10 studies in Leukemia by Medical College of Wisconsin, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
T cell depletion utilizing the CliniMACS device will allow more precise, specific and controlled graft engineering of peripheral blood stem cells from unrelated and partially matched related donors without an increase in relapse or graft rejection and grade III or IV acute graft versus host disease (GVHD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receiving an unrelated donor or partially matched related donor.
Device: CliniMACS (CD+3, CD+19 depletion) · Other: HSCT
For the patient's whose donors are haploidentical or a 2 antigen mismatched where one of the mismatches includes DRB1
Device: CliniMACS (CD 34+ positive selection) · Other: HSCT
Patient's in Stratum 1 will receive grafts that have undergone CD3+, CD19+ depletion
Patient's in Stratum 2 will receive peripheral blood progenitor cells that have undergone CD34+ selection
Peripheral Blood Stem Cell Transplant
To measure the incidence and quality of engraftment
Time frame: Weekly for first 100 days, 6 months and 1 year
Evaluate the incidence of acute Graft versus Health Disease and treatment related mortality.
Time frame: weekly for the first 100 days and then 6 and 12 months post transplant date
The record gives a start of May 2008, a primary completion of Aug 2016 and a completion of Apr 2020. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical College of Wisconsin →